Abbreviations {#nomen0010}
=============

BSA

:   bovine serum albumin

DPP-4

:   dipeptidyl peptidase-4

DMEM

:   Dulbecco\'s Modified Eagle\'s Medium

FBS

:   fetal bovine serum

GIP

:   glucose-dependent insulinotropic polypeptide

GLP-1

:   glucagon-like peptide-1

KRB

:   Krebs Ringer Buffer

OGTT

:   oral glucose tolerance test

PBS

:   phosphate buffered saline

PC

:   prohormone convertase

T2DM

:   type 2 diabetes mellitus

1. Introduction {#sec1}
===============

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretins released from the gut that promote insulin secretion from pancreatic beta cells in a meal dependent manner [@bib1]. Additionally, GIP and GLP-1 increase insulin biosynthesis, promote beta cell proliferation and reduce beta cell apoptosis [@bib1]. Pro-GIP and proglucagon are processed to GIP and GLP-1, respectively, in the gut primarily by prohormone convertase (PC) 1/3 [@bib2]. Mature GIP predominantly consists of 42 amino acids and is secreted from K-cells concentrated in the upper small intestine [@bib1]. The major insulinotropic forms of GLP-1 are GLP-1(7--36)~NH2~ and GLP-1(7--37), which are liberated from proglucagon via the action of PC 1/3 and released from L-cells mainly distributed in the lower small intestine and colon [@bib1]. Both incretin hormones are rapidly cleaved after secretion by dipeptidyl peptidase-4 (DPP-4) into truncated forms that are no longer insulinotropic [@bib1]. Although recently developed ELISA kits may be able to detect active forms of GIP and GLP-1, it is unclear if these ELISAs can accurately quantify biologically active forms of the hormones because they are antibody based measurements, and immunoreactivity may not always coincide with bioactivity of peptide hormones. Moreover, recent reports suggest that a shorter form GIP(1--30)~NH2~ is secreted from the pancreas and the gut [@bib2], [@bib3], and this form has insulinotropic activity almost equivalent to GIP(1--42) [@bib2]. It was unclear, however, if this form is detectable by active GIP ELISAs.

DPP-4 inhibitors are widely used to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), and they are a particularly effective treatment for non-obese diabetes patients in East Asia. More than 70% of Japanese patients treated with anti-diabetic drugs receive DPP4 inhibitors or GLP-1 mimetics and approximately 60% receive a DPP-4 inhibitor as a first-line therapy [@bib4]. We wished to evaluate how DPP-4 inhibitors alter the levels of GIP and GLP-1, using both conventional commercially available assays and novel cell-based, receptor-mediated bioassays. Our results using the bioassays indicate that active GIP levels increase dramatically following DPP-4 inhibitor treatment, much greater than that of GLP-1, and this finding is not revealed by the ELISAs we tested.

2. Material and methods {#sec2}
=======================

2.1. Subjects and study protocol {#sec2.1}
--------------------------------

We recruited 10 non-diabetic subjects with informed consent for a 75 g OGTT male, age 32.3 ± 5.6 years, BMI 23.3 ± 5.6 kg/m^2^, HbA1c 5.1 ± 0.28% (31.5 ± 2.7 mmol/mol); average ± SD. We performed a second OGTT after DPP-4 inhibitor treatment (sitagliptin: 100 mg/day for 3 days) in 5 subjects following the first OGTT without DPP-4 inhibitor treatment (male, age 35.2 ± 6.3 years, BMI 23.3 ± 3.0 kg/m^2^, HbA1c 5.1 ± 0.31% (31.8 ± 3.1 mmol/mol); average ± SD). The study was performed in accordance with the Declaration of Helsinki, and the research protocol was approved by the Research Ethics Committee of Asahikawa Medical University).

2.2. Study protocol {#sec2.2}
-------------------

All subjects were fasted for 10--12 h before the OGTTs. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 min, and blood samples were collected at the same time points using blood collection tubes containing DPP-4 inhibitor (P800; BD, Tokyo, Japan). The plasma samples were separated by centrifugation (3000 RPM for 15 min) at 4 °C, aliquoted, and stored at −80 °C until the assays.

2.3. Assays {#sec2.3}
-----------

We measured blood glucose and plasma insulin levels (ELISA \# 10-1113-01, Mercodia, Uppsala, Sweden) at 0, 15, 30, 60, 90, and 120 min of the OGTT. We measured plasma total GIP (EZHGIP-54K, Millipore, Tokyo, Japan) and total GLP-1 (EZGLP1T-36K, Millipore, Tokyo, Japan) levels by ELISA according to the manufacturer\'s instructions, while active GIP and active GLP-1 levels by our bioassays employing HEK293 cell lines stably co-transfected with human forms of either the GIP receptor (GIPR) or GLP-1 receptor (GLP-1R), and a cyclic AMP-inducible luciferase expression construct. Each assay was performed on previously unthawed plasma aliquots. We also utilized a commercial active GIP ELISA kit (\# 27201, IBL, Fujioka, Japan) to assay the samples from 5 subjects collected during the OGTT at 0 and 15 min with or without the sitagliptin administration.

For further details for the bioassays, stably selected co-transfected HEK293 cell lines were cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM) (25 mmol/l glucose) with 10% (v/v) fetal bovine serum (FBS) (GIBCO, Tokyo, Japan), 100 IU/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Tokyo, Japan) at 37 °C in 5% CO~2~. Cells were incubated overnight in 96-well plates (100,000 cells/well). Media was then replaced with samples or synthetic peptide standards (GIP bioassay: GIP(1--42), GIP(1--30)~NH2,~ GLP-1(7--36)~NH2~, glucagon: 10^−13^--10^−6^ mol/l, GLP-1 bioassay: GLP-1(7--36)~NH2~, GIP(1--42), GIP(1--30)~NH2~ and glucagon: 10^−13^--10^−9^ mol/l) that were diluted in Krebs Ringer Buffer (KRB) (pH 7.4) containing 0.5% (w/v) bovine serum albumin (BSA) (Sigma--Aldrich, Tokyo, Japan) and incubated for 5 h at 37 °C in 5% CO~2~. We diluted plasma samples with KRB before active GIP and GLP-1 measurement by bioassay (GIP: 20-fold dilution, GLP-1: 50-fold dilution). After incubation, we measured luciferase activity with the Bright-Glo Assay Kit (Promega, Madison, WI, USA) using a Thermo Scientific Appliskan (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer\'s instructions and calculated the hormone concentrations as previously described [@bib5].

2.4. Peptides {#sec2.4}
-------------

GIP(1--42), GLP-1(7--36)~NH2~ and glucagon were purchased from Peptide Institute (Osaka, Japan). GIP(1--30)~NH2~ was purchased from Phoenix Pharmaceuticals (Burlingame, CA, USA).

2.5. Statistical analysis {#sec2.5}
-------------------------

Data are expressed as mean ± SEM unless otherwise stated. Statistical analysis was performed by two-way repeated ANOVA followed by the Bonferroni post hoc test. Data were analyzed using commercial software (Prism 5; GraphPad, San Diego, CA, USA) and p \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. The receptor-mediated GIP bioassay detected both GIP(1--42) and GIP(1--30)~NH2~ whereas the GIP ELISA kits did not detect GIP(1--30)~NH2~ {#sec3.1}
----------------------------------------------------------------------------------------------------------------------------------------------

To evaluate the specificity and the characteristics of the bioassays, we examined their responsiveness and specificity with several synthetic glucagon-related peptides. In the GIP bioassay, GIP(1--42) and GIP(1--30)~NH2~ almost equivalently increased luciferase activity in a concentration dependent manner. GLP-1(7--36)~NH2~ and glucagon did not increase luciferase activity at any concentration tested ([Figure 1](#fig1){ref-type="fig"}A). In contrast, total or active GIP ELISA kits did not detect GIP(1--30)~NH2~ ([Figure S1A and B](#appsec3){ref-type="sec"}). In the GLP-1 bioassay, GLP-1(7--36)~NH2~ increased luciferase activity in a concentration dependent manner. Glucagon induced luciferase activity at concentrations greater than approximately 10^−11^ mol/l, consistent with prior studies demonstrating relatively low affinity binding of glucagon to GLP-1 receptors [@bib6]. In contrast, GIP(1--42) did not increase luciferase activity in the GLP-1 bioassay ([Figure 1](#fig1){ref-type="fig"}B). The DPP-4 inhibitor sitagliptin did not significantly alter luciferase activity in the GIP bioassay ([Figure S2](#appsec3){ref-type="sec"}).

3.2. The administration of a DPP-4 inhibitor markedly increased bioactive GIP levels after glucose load in non-diabetic subjects {#sec3.2}
--------------------------------------------------------------------------------------------------------------------------------

During the OGTTs, blood glucose levels peaked at 30 min and insulin levels reached a peak at 30--60 min ([Figure 2](#fig2){ref-type="fig"}A and B). Total GIP levels in the samples measured by ELISA rapidly increased from 0 to 15 min and subsequently gradually increased up to a peak at 120 min (59.2 ± 8.3 pmol/l; [Figure 2](#fig2){ref-type="fig"}C). In contrast, active GIP levels determined by the bioassay peaked at 15 min (43.4 ± 6.4 pmol/l; [Figure 2](#fig2){ref-type="fig"}C). Total GLP-1 levels as measured by ELISA increased to 30 min and remained at similar levels up to 120 min (23.4 ± 2.0 pmol/l; [Figure 2](#fig2){ref-type="fig"}D). Active GLP-1 levels by the bioassay did not show an apparent peak, averaging 7.9 ± 0.35 pmol/l ([Figure 2](#fig2){ref-type="fig"}D).

The three-day administration of a DPP-4 inhibitor tended to lower blood glucose levels during an OGTT but without statistical difference ([Figure 3](#fig3){ref-type="fig"}A). Postprandial plasma insulin levels were increased approximately 2-fold at several time points compared to before DPP-4 inhibitor administration ([Figure 3](#fig3){ref-type="fig"}B). The active GIP levels were markedly elevated at all time points in all 5 subjects following treatment with the DPP-4 inhibitor, but, given the variability, statistical significance was only achieved at two time points ([Figure 3](#fig3){ref-type="fig"}C). Active GIP levels measured using the bioassay at 15 min were approximately 20-fold greater than values at the same time point before DPP-4 inhibitor treatment ([Figure 3](#fig3){ref-type="fig"}C). In contrast, total GIP levels by ELISA at 15 min were 1.5-fold greater ([Figure 3](#fig3){ref-type="fig"}D) while active GIP levels determined by ELISA were 2.1-fold greater than values at the same time point before DPP-4 inhibitor treatment ([Figure 3](#fig3){ref-type="fig"}E). Administration of other DPP-4 inhibitors (linagliptin: 5 mg/day and vildagliptin: 100 mg/day) increased active GIP as determined by the bioassay during OGTT similarly to sitagliptin (data not shown).

Unlike active GIP, active GLP-1 levels by the bioassay were only modestly elevated after the DPP-4 inhibitor treatment from 0 to 120 min and increased by 1.4-fold at 15 min after oral glucose load ([Figure 3](#fig3){ref-type="fig"}F). In contrast, total GLP-1 levels as determined by ELISA were decreased after DPP-4 inhibitor treatment ([Figure 3](#fig3){ref-type="fig"}G).

4. Discussion {#sec4}
=============

Plasma GIP and GLP-1 levels are typically measured by ELISA, a highly sensitive immunological method to detect specific antigens. However, it can be difficult for these assays to distinguish antigens with similar epitopes. Indeed, it has been demonstrated that commercially available glucagon ELISA kits have cross-reactivity with glicentin and other proglucagon-derived peptides [@bib7], [@bib8], [@bib9]. The specificity and sensitivity of commercially available kits for the analysis of GLP-1 levels also vary considerably [@bib10]. Additionally, the immunological values obtained with these assays may not accurately reflect the total biological activity as some immunoreactive variants may not be bioactive, and some bioactive forms may not be immunoreactive. The receptor-mediated method we employed here reflects incretin receptor binding ability and intracellular signaling through cyclic AMP production. Therefore, the receptor-mediated bioassays may better reflect biological activity of intact incretin hormones than conventional immunological based methods. For example, we found that GLP-1, glucagon, GLP-2, oxyntomodulin, secretin and mini-glucagon (glucagon(19--29)) did not cross-react in the GIP bioassay, even at concentrations as high as 100 nM ([Figure 1](#fig1){ref-type="fig"} and data not shown). Nevertheless, we cannot discount the possibility that there are fragments of GIP and GLP-1, such as the DPP-4 products GIP(3--42) and GLP-1(9--36)~NH2~, that may have biological actions mediated by non-cyclic AMP intracellular signaling pathways and thus not detected by our bioassays.

GIP is localized in gut K-cells with PC 1/3, which liberates the 42 amino acid mature form of GIP from Pro-GIP [@bib3]. Recently, it was reported that Pro-GIP is processed to GIP(1--30)~NH2~ in pancreatic alpha cells and in the gut by PC2 [@bib2], [@bib3] and demonstrated that GIP(1--30)~NH2~ possesses insulinotropic activity similar to GIP(1--42) [@bib2]. DPP-4 exists as a soluble form in circulation [@bib11] or a membrane bound form in many tissues including endocrine cells of the pancreatic islets [@bib12]. Moreover, recent studies indicate that GIP is particularly susceptible to DPP-4 activity in hematopoietic and endothelial cells [@bib13]. Therefore, circulating GIP(1--30)~NH2~ concentrations are likely very low in the absence of DPP-4 inhibitor treatment, because GIP(1--30)~NH2~ is anticipated to be rapidly cleaved by DPP-4 like GIP(1--42) [@bib14]. In the absence of DPP-4 inhibitor treatment, there may be relatively large amounts of circulating GIP(3--30)~NH2~ with presently unappreciated biological actions. The administration of DPP-4 inhibitor may reduce GIP(1--30)~NH2~ inactivation, and thus GIP(1--30)~NH2~ may have contributed to the markedly elevated bioactive GIP levels we measured in subjects following administration of the DPP-4 inhibitor. While our GIP bioassay characterization excludes the possibility of significant contributions from major glucagon-related peptides, some of which are DPP-4 substrates, we cannot exclude the possibility that there are other peptides activating the GIP receptor once stabilized by 3 days of DPP-4 inhibitor treatment.

In this study, active GLP-1 levels by the bioassay were modestly elevated after the DPP-4 inhibitor treatment from 0 to 120 min. In contrast, total GLP-1 levels as determined by ELISA were decreased after DPP-4 inhibitor treatment. Our findings are similar to that of Nauck et al. who also demonstrated that DPP-4 inhibitor treatment increased active GLP-1 and reduced total GLP-1 levels [@bib15]. It is reported that GLP-1(7--36)~NH2~ stimulates intestinal somatostatin release [@bib16] and somatostatin inhibits GLP-1 secretion from the gut [@bib17]. Consequently, an increase in active GLP-1 levels by DPP-4 inhibition could promote somatostatin secretion which ultimately reduces intestinal GLP-1 secretion. It is also possible that increased bioactive GIP levels might act to reduce GLP-1 levels, as GIP infusion has been reported to significantly decrease postprandial plasma GLP-1 levels during a mixed meal in humans [@bib18].

During the OGTTs, DPP-4 inhibitor administration enhanced postprandial insulin levels and dramatically increased active GIP levels measured by bioassay. GIP stimulates insulin secretion and is reported to enhance glucagon release especially in the hypoglycemic state [@bib19]. It is possible that in our studies with non-diabetic subjects treated with DPP-4 inhibitor, GIP-stimulated glucagon secretion might partially explain the modest reduction of glucose levels despite the hyperinsulinemia. DPP-4 inhibition may have also augmented the biological activity of glucagon [@bib20], although the biological importance of DPP-4-mediated glucagon cleavage for glucagon action in humans remains to be clarified.

It has been reported that the insulinotropic action of GIP is severely diminished in patients with T2DM [@bib21], [@bib22], [@bib23]. As a result, it is generally assumed that GIP contributes little to the therapeutic efficacy of DPP-4 inhibitors. Moreover, there was no added therapeutic benefit following the addition of a dipeptidyl peptidase-4 inhibitor to ongoing therapy with a GLP-1 receptor agonist, despite increased plasma levels of immunoreactive intact GIP (and GLP-1) [@bib24]. However, administration of the GLP-1 receptor antagonist exendin(9--39) only blocks ∼50% of the glucose lowering effect of DPP-4 inhibitor treatment in humans [@bib15], [@bib25], suggesting that DPP-4-- sensitive factors beyond circulating GLP-1 substantially contribute to the actions of DPP-4 inhibitors. In agreement, DPP-4 inhibitor treatment in mice with GLP-1 receptor knockout still increased plasma insulin levels and improved glucose tolerance similarly as in wildtype mice [@bib26]. GIP is a likely candidate, because DPP-4 therapy is completely ineffective in mice with combined knockout of GIP and GLP-1 receptors, suggesting that extended activity of both GIP and GLP-1 accounts for the full glucose lowering actions of DPP-4 inhibitors [@bib26], [@bib27]. Moreover, a unimolecular GLP-1/GIP co-agonist demonstrated enhanced antihyperglycemic and insulinotropic efficacy relative to selective GLP-1 agonists in diabetic rodents and humans [@bib28]. Our findings of a particularly large increase in bioactive GIP levels in humans treated with DPP-4 inhibitors, combined with observations that administration of a GIP(1--30) analog can improve glycemic control in diabetic rodents [@bib29], supports the notion that increased GIP bioactivity contributes significantly to the therapeutic benefit of DPP-4 therapy.

Our study was limited to assessing glucose-stimulated incretin responses in healthy subjects during an OGTT. However, incretin secretion is also simulated by fat ingestion [@bib1]. Therefore, future studies should examine bioactive incretin responses to other nutrients too. In addition, there are miscellaneous reports with ELISAs indicating that plasma GIP and GLP-1 levels in subjects with T2DM are increased, comparable, or even decreased relative to those in healthy subjects [@bib30], [@bib31]. The bioassays described here may be useful tools to measure bioactive incretin levels to resolve these discrepancies.

In conclusion, our studies suggest that ELISAs may typically underestimate the levels of bioactive incretins, particularly assays that do not detect GIP(1--30)~NH2~. Moreover, we find that DPP-4 inhibitor treatment has a much greater impact on plasma bioactive GIP levels than bioactive GLP-1 levels in healthy subjects. Therefore, the contribution of GIP to the therapeutic efficacy of DPP-4 inhibitor treatment warrants additional examination.
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![The receptor-mediated GIP bioassay detects both GIP(1--42) and GIP(1--30)~NH2~. The responsiveness and specificity of (A) GIP and (B) GLP-1 receptor-mediated bioassays with GIP, GLP-1, and glucagon peptides. White triangles, GIP(1--42); white inverted triangles, GIP(1--30)~NH2~; black triangles, GLP-1(7--36)~NH2~; black inverted triangles, glucagon. Data are presented as mean ± SEM.](gr1){#fig1}

![Active GIP levels by bioassay showed an apparent peak at 15 min during a 75 g OGTT. Blood glucose (A), plasma insulin (B), plasma active (bioassay), and total (ELISA) GIP (C) and GLP-1 (D) levels in samples collected at the indicated times during a 75 g OGTT (n = 10 in each group). For (C) and (D), white circles, total GIP; black circles, active GIP; white squares, total GLP-1; black squares, active GLP-1. Data are presented as mean ± SEM. \*p \< 0.05, \*\*\*\*p \< 0.0001.](gr2){#fig2}

![The administration of a DPP-4 inhibitor markedly increased bioactive GIP and plasma insulin levels after glucose load in non-diabetic subjects. Blood glucose, plasma insulin, plasma active, and total GIP and GLP-1 levels before and after DPP-4 inhibitor treatment (n = 5 in each group). (A) Blood glucose. (B) Plasma insulin levels. (C) Active GIP levels by bioassay. (D) Total GIP levels by ELISA. (E) Active GIP levels by ELISA at 0 and 15 min. (F) Active GLP-1 levels by bioassay. (G) Total GLP-1 levels by ELISA. Data are presented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. White circles and white bars, before DPP-4 inhibitor treatment; black circles and black bars, after DPP-4 inhibitor treatment.](gr3){#fig3}
